» Articles » PMID: 9600288

Recent Trends in Diagnosis and Treatment of Clostridium Difficile in a Tertiary Care Facility

Overview
Journal Am J Surg
Specialty General Surgery
Date 1998 May 26
PMID 9600288
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: With the prevalence of antibiotic use, the diagnosis and management of Clostridium difficile disease requires assessment.

Methods: In a retrospective review, patients with a positive culture, toxin, or both during 1 year were identified. Recent literature was reviewed. Results of culture and toxin, prior antibiotic use, antibiotic treatment history and cost were analyzed.

Results: Of 592 patients tested, 101 were positive; 96 of 101 were available for review. Of those positive tested for both, 45% were positive for toxin and culture. Sixty-two of 96 were treated with antibiotics; metronidazole was used in 90%. Ten of 62 antibiotic treatments were changed (mean 3 days). Ten days of metronidazole is 1/200th the cost of vancomycin.

Conclusions: In 55% of the positive cases in which culture and toxin were obtained, one test was negative. As metronidazole's efficacy and cost compares favorably with vancomycin, metronidazole is the drug of choice. Any changes made to antibiotic regimens occurred prior to the 6 days recommended in the literature.

Citing Articles

Cost analysis of hospitalized Clostridium difficile-associated diarrhea (CDAD).

Hubner C, Hubner N, Muhr M, Claus F, Leesch H, Kramer A GMS Hyg Infect Control. 2015; 10:Doc13.

PMID: 26550553 PMC: 4635781. DOI: 10.3205/dgkh000256.


The economic impact of Clostridium difficile infection: a systematic review.

Nanwa N, Kendzerska T, Krahn M, Kwong J, Daneman N, Witteman W Am J Gastroenterol. 2015; 110(4):511-9.

PMID: 25848925 DOI: 10.1038/ajg.2015.48.


A review of the economics of treating Clostridium difficile infection.

Mergenhagen K, Wojciechowski A, Paladino J Pharmacoeconomics. 2014; 32(7):639-50.

PMID: 24807468 DOI: 10.1007/s40273-014-0161-y.


Pseudomembranous Colitis Caused by C. difficile.

Surawicz , McFarland Curr Treat Options Gastroenterol. 2000; 3(3):203-210.

PMID: 11097737 DOI: 10.1007/s11938-000-0023-x.